Shaily Engineering Plastics Ltd Q1 FY27 Earnings Call: Guides 36M+ Pen Device Demand, Margin Expands 120 bps to 29.7%

Shaily Engineering Plastics Ltd held its Q1 FY27 earnings call on August 08, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Healthcare-Led Growth Drives 14% Revenue Uptick

• Rs.281 Cr consolidated revenue — up 14% YoY in Q1 FY 2026-2027 from Rs.247 Cr in Q1 FY 2025-2026, led by healthcare segment strength.
• EBITDA of Rs.83 Cr — up 18% YoY from Rs.70 Cr, with margin expanding 120 bps to 29.7% in Q1 FY 2026-2027.
• PAT of Rs.48 Cr — up 17% YoY from Rs.41 Cr, with PAT margin at 17.1% (+40 bps) in Q1 FY 2026-2027.
• Machine utilisation improved to 50.2% — from 48.7% in Q1 FY 2025-2026, reflecting better capacity absorption.
• Exports comprised 58% of revenue — down from 76% in Q1 FY 2025-2026, driven by a growing domestic business that supplies global markets through Indian pharmaceutical customers.

Pen Injector Dominance Expands with 85% Healthcare Growth

• Healthcare segment revenue surged 85% YoY to Rs.142 Cr — becoming the largest segment at 51% of consolidated revenue in Q1 FY 2026-2027.
• Total installed pen injector capacity on track to reach 75 million units per annum — by end of September FY 2026-2027, with an additional 25 million capacity coming online.
• Q1 delivery device volumes hit ~9 million units — with 50-60% being GLP-1 devices and the remainder insulin plus other molecules.
• Management reaffirmed demand guidance of 36 million pens for FY 2026-2027 — and noted it "should be able to go beyond 36 million" units, though short-term supply-chain issues at customer partners remain a risk.
• In Canada, management expects to be "quite dominant"; in Brazil, currently #2 — with expectation of majority share, and management expects to be the largest player in new markets (Mexico, Turkey, Saudi Arabia).
• Two new platform projects signed — and orders received for injector pen supplies following regulatory approvals in Canada and Brazil.
• Chinese competitors offering GLP-1 device copycats at $1.50-$1.70 per unit — potentially infringing patents; Shaily's pricing remains above $2 per unit, and management expressed limited concern.

Consumer Segment Declines as Healthcare and Electronics Scale

• Consumer segment revenue fell 24% YoY to Rs.116 Cr — impacted by softer demand in home furnishings in Europe and the US in Q1 FY 2026-2027; India accounted for only ~2% of consumer product supply, making the domestic furniture trend negligible.
• Consumer electronics: new plant started commercial supply; won 5 new components from a new customer — with supply expected before end of FY 2026-2027; management projected (non-guidance) reaching $10 million revenue within 24 to 30 months from August 2026.
• Semiconductor tray revenue expected to commence from Q4 FY 2026-2027 — with initial investment of ~Rs.5 Cr in existing facilities; further investment depends on customer capacity ramp in India; fewer than 12 competitors globally for these highly specialised consumables.
• Industrial segment grew 25% YoY to Rs.23 Cr — supported by new customer additions in engineering applications and consumer electronics in Q1 FY 2026-2027.
• Consumer electronics new component supply begins end of FY 2026-2027 — with revenue ramp primarily from FY 2027-2028; future south India plant investment estimated at Rs.80-100 Cr.
• Management guided that healthcare will grow and semiconductor/consumer electronics will expand — with domestic revenue expected to grow as a percentage of total in FY 2026-2027.

Margin Expansion Continues Despite Input Cost Headwinds

• EBITDA margin expanded 120 bps to 29.7% — with PAT margin up 40 bps to 17.1% in Q1 FY 2026-2027, driven by mix shift toward healthcare.
• Gross margin declined sequentially in Q1 FY 2026-2027 — due to commodity price increases and higher freight costs; pass-through pricing was delayed, with management expecting normalisation by Q3 FY 2026-2027.
• Efficiency on the new production line improved by 9% — additional equipment expected by end of Q2 FY 2026-2027 should provide a further 30% jump in efficiency.
• Second production line delayed to allow supplier to reach 80%+ efficiency before shipping — once installed (~1-2 months from call date), similar efficiency targeted within a month or two.
• Contracts are not cost-plus but volume- and market-driven — with annual price reviews factoring inflation and polymer costs.
• UK subsidiary saw a timing-related revenue drop in Q1 — management expects recovery over the remaining three quarters of FY 2026-2027; full-year growth of at least 15% was not confirmed by management.

Next-Generation Devices Target $6-$35 ASPs and 99.999% Reliability

• Emergency-use auto-injector closure targeted by end of FY 2026-2027 — requiring statistically proven 99.999% reliability on activation; management cited "high reliability mandated by the US FDA" as a design requirement.
• Reusable auto-injector performance testing planned for August or early September 2026 — with first showcase at CPHI Milan and launch targeted by end of FY 2026-2027; management cited "the industry generation of ~1 billion auto-injector units in landfill annually" as the market rationale.
• On-body injector for oncology seeking a partnership to advance development — prototyped 2-3 years ago, with delivery range of 3 ml to 15 ml (up to 23 ml possible).
• Emergency use device cost estimated at $6 to $10 per device — with revenue potential in "mid-single-digit millions to high-single-digit, maybe low-double-digit millions" (period unspecified).
• On-body injector cost estimated at $15 to $25 or $35 — with revenue at "very low millions, maybe one or two" but described as high-value, high-margin therapy (period unspecified).
• Management denied any work with Cipla on inhalers — stating "we are not doing any inhalers at the moment."
• Management expressed confidence in securing an innovator partnership within four to six quarters — i.e., by approximately FY 2027-2028, supported by two new dedicated senior business development heads for the US and Europe.

FY 2026-2027 Guidance Maintained with Cautious Optimism

• Management maintained pen device demand guidance of 36 million units for FY 2026-2027 — with confidence in scaling further in FY 2027-2028; the company has supplied 5-10 million pens to date across fewer than half a dozen launched customers.
• Consumer segment expected to "probably not grow" in FY 2026-2027 — per management's guidance from Q4 FY 2025-2026, reaffirmed in this call; long-term performance unlikely to materially impact the bottom line over a 3-5-year horizon.
• Abu Dhabi facility must be in production by end of FY 2027-2028 — with 50-55% of capacity already committed or indicated; management is "targeting European market openings in 2028 and global insulin markets in 2030-2031".
• Semiconductor revenue to commence from Q4 FY 2026-2027 — and consumer electronics new component supply begins before end of FY 2026-2027, with meaningful ramp from FY 2027-2028.
• Near-term demand softness persists in certain end markets — but management stated that the diversified business model and disciplined execution are expected to support future performance.
• Management declined to quantify incremental TAM from selumutide approvals in Canada and Brazil — referring analysts to external research reports, stating the company is "not competent to discuss that market."